Zoetis (ZTS) Stock Forecast & Price Target

$191.00

-3.44 (-1.77%)

(As of 10/17/2024 ET)

Zoetis - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 10 Analyst Ratings

Sell
0

Hold
0

Buy
10

Based on 10 Wall Street analysts who have issued ratings for Zoetis in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 9 have given a buy rating, and 1 has given a strong buy rating for ZTS.

Consensus Price Target

$221.44
15.94% Upside

According to the 10 analysts' twelve-month price targets for Zoetis, the average price target is $221.44. The highest price target for ZTS is $237.00, while the lowest price target for ZTS is $196.00. The average price target represents a forecasted upside of 15.94% from the current price of $191.00.

Get the Latest News and Ratings for ZTS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zoetis and its competitors.

ZTS Analyst Ratings Over Time

Type	Current Forecast 10/18/23 to 10/17/24	1 Month Ago 9/18/23 to 9/17/24	3 Months Ago 7/20/23 to 7/19/24	1 Year Ago 10/18/22 to 10/18/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$221.44	$217.11	$211.75	$220.88
Forecasted Upside	15.94% Upside	10.92% Upside	18.50% Upside	30.28% Upside
Consensus Rating	Buy	Buy	Buy	Buy

[Urgent] Starlink Set For The Largest IPO In History? (Ad)

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

ZTS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZTS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zoetis Stock vs. The Competition

Type	Zoetis	Medical Companies	S&P 500
Consensus Rating Score	3.10	2.79	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	15.78% Upside	12,992.65% Upside	6.35% Upside
News Sentiment Rating	Positive News See Recent ZTS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/11/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$225.00 ➝ $230.00	+20.70%
9/18/2024	Stifel Nicolaus 4 of 5 stars		Boost Target	Buy ➝ Buy	$200.00 ➝ $210.00	+7.29%
8/14/2024	Piper Sandler 2 of 5 stars		Boost Target	Overweight ➝ Overweight	$195.00 ➝ $210.00	+14.14%
8/12/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Massaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$220.00 ➝ $225.00	+22.75%
8/9/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$230.00 ➝ $225.00	+36.80%
Get the Latest News and Ratings for ZTS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.
5/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$223.00 ➝ $196.00	+17.58%
4/23/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$260.00 ➝ $230.00	+54.58%
12/19/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$230.00	+16.03%
12/7/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$237.00	+30.22%
4/11/2023	Bank Of America (Bofa) Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$180.00 ➝ $200.00	+16.74%
11/15/2022	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$264.00 ➝ $248.00	+69.34%
11/3/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Vazquez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:09 AM ET.

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 11, 2024. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

Zoetis
Bull Case

Here are some ways that investors could benefit from investing in Zoetis Inc.:

Zoetis Inc. reported strong earnings results, beating analysts' consensus estimates, indicating a healthy financial performance.
The company has a high return on equity of 50.67%, showcasing efficient utilization of shareholder equity to generate profits.
Recent Wall Street analyst reports have given Zoetis Inc. positive ratings, with price targets indicating potential stock price growth.
Institutional investors, such as Hsbc Holdings PLC and Czech National Bank, have been increasing their stakes in Zoetis Inc., reflecting confidence in the company's future prospects.
Zoetis Inc. has a strong market capitalization of $89.65 billion, indicating its position as a significant player in the industry.

Zoetis
Bear Case

Investors should be bearish about investing in Zoetis Inc. for these reasons:

Zoetis Inc.'s stock price has experienced fluctuations, which may introduce volatility and uncertainty for investors.
The company's price-to-earnings ratio of 37.86 suggests that the stock may be relatively expensive compared to industry peers, potentially limiting immediate upside potential.
While Zoetis Inc. has shown revenue growth, the price-to-earnings-growth ratio of 2.98 indicates that the stock may be overvalued based on its growth prospects.
Debt-to-equity ratio of 1.32 may raise concerns about the company's leverage and financial risk, impacting investor confidence.
Recent trading volumes and stock price movements suggest potential market sentiment shifts that could affect short-term stock performance.

ZTS Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Zoetis is $221.44, with a high forecast of $237.00 and a low forecast of $196.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZTS shares.
: According to analysts, Zoetis's stock has a predicted upside of 15.94% based on their 12-month stock forecasts.
: Over the previous 90 days, Zoetis's stock had 1 upgrade by analysts.
: Zoetis has been rated by research analysts at Argus, BTIG Research, JPMorgan Chase & Co., Piper Sandler, and Stifel Nicolaus in the past 90 days.
: Analysts like Zoetis more than other "medical" companies. The consensus rating for Zoetis is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZTS compares to other companies.